Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Infectious Disease/Chronic Hepatitis

Infectious Disease

Chronic Hepatitis

75

Pipeline Programs↗

100

Active Trials↗

96

Companies Involved↗

Chronic Hepatitis is a moderately active landscape with 75 programs across 96 companies. The most active players are Gilead, Fujian Akeylink Biotechnology Co., Ltd., Barinthus Biotherapeutics. 16 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

72/100

Pipeline Velocity

62/100

Mech. Concentration

40/100

Completion Rate

84/100

Attrition Rate

12/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Gilead

3 programs

Fujian Akeylink Biotechnology Co., Ltd.

2 programs

Barinthus Biotherapeutics

2 programs

Haisco Pharmaceutical Group Co., Ltd.

1 program

Beijing Continent Pharmaceutical Co, Ltd.

1 program

Ausper Biopharma Co., Ltd.

1 program

Pipeline

Programs by Phase

Preclinical34

Methylprednisolone

Pfizer

Galactose

Northwell Health

Direct Acting Antivirals

Post Graduate Institute of Medical Education and Research, Chandigarh

Ribavarin

Merck & Co.

Interferon

Sanofi

Phase 16

Liocyx-M

Lion TCR Pte. Ltd.

TCR-T

Lion TCR Pte. Ltd.

EPI-003

Epigenic Therapeutics, Inc

SN2001

Chimivac INC

Wgc0201

Jiyan Liu

Phase 219

Selgantolimod

Gilead

Nivolumab

Bristol-Myers Squibb

VIR-3434

Vir Biotechnology, Inc.

Chadox1-HBV

Barinthus Biotherapeutics

MVA-HBV

Barinthus Biotherapeutics

Phase 316

Peginterferon Alfa-2b

Merck & Co.

Hydronidone

Beijing Continent Pharmaceutical Co, Ltd.

Azvudine

Henan Genuine Biotech Co., Ltd.

Placeb

University of Oxford

Tenofovir DF

Gilead

Approved

No programs

Analysis

Modality Breakdown

89%

Small molecule

58 of 65 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 65 classified programs, each share of the total. Modality classified for 96% of 75 pipeline programs.

Analysis

Trial Status

1,070

clinical trials

Completed682 · 64%

Unknown status154 · 14%

Terminated95 · 9%

Recruiting44 · 4%

Withdrawn33 · 3%

Active, not recruiting32 · 3%

Other30 · 3%

Clinical Trials

Trial Activity

1070 trials

A Phase 2b/3, Open-Label, Multicenter Trial Evaluating the Efficacy and Safety of Switching to Brelovitug for the Treatment of Chronic Hepatitis Delta Infection in Participants Receiving Bulevirtide (AZURE-3)

Recruiting·MMirum Pharmaceuticals, Inc.·Preclinical·NCT07454837·120 enrolled

A Phase 2 Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Combination Therapy of BRII-179, BRII-835 and Pegylated Interferon Alpha (PEG-IFNα) in Participants With Chronic Hepatitis B Virus (HBV) Infection (ENHANCE)

Recruiting·BBrii Biosciences Limited·Phase 2·NCT06650852·250 enrolled

A Global, Randomized, Open-label, Multicenter Phase 3 Trial Evaluating BJT-778 vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)

Recruiting·MMirum Pharmaceuticals, Inc.·Phase 3·NCT07200908·172 enrolled

Single-Center Cohort Study on the Impact of Functional Cure of Chronic Hepatitis B on Patient-Reported Outcomes (PROs)

Recruiting·—·N/A·NCT07855029·400 enrolled

A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (A)

Recruiting·TThe Second Affiliated Hospital of Chongqing Medical University·Phase 2·NCT07852091·1,200 enrolled

A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (B)

Recruiting·TThe Second Affiliated Hospital of Chongqing Medical University·Phase 2·NCT07845058·1,200 enrolled

A Phase 1, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics, And Preliminary Efficacy of Single and Multiple Ascending Doses of IB-001 in Healthy Participants and Participants With Chronic Hepatitis B

Recruiting·IIntegerBio·Phase 1·NCT07389044·88 enrolled

A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (A)

Recruiting·TThe Second Affiliated Hospital of Chongqing Medical University·Phase 2·NCT05769816·120 enrolled

A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (B)

Recruiting·TThe Second Affiliated Hospital of Chongqing Medical University·Phase 2·NCT05771402·120 enrolled

ASC22 Combined With Peg-IFNa in Achieving Functional Cure in Patients With Chronic Hepatitis B Virus Infection

Recruiting·TThe Second Affiliated Hospital of Chongqing Medical University·Approved·NCT07573943·120 enrolled

Safety and Efficacy of Tenofovir Alafenamide to Prevent Mother-to-child Transmission of Hepatitis B Virus in Middle/Late Pregnancies With High Hepatitis B Virus DNA Load: A Prospective Multicenter Cohort Study

Recruiting·—·N/A·NCT05466071·200 enrolled

Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta

Recruiting· Gilead logo

Gilead·Preclinical·NCT07096193·200 enrolled

A Multicenter, Randomized, Controlled, Open-label, Phase III Study to Assess Efficacy and Safety of Libevitug Injection in Participants With Chronic Hepatitis Delta Virus Infection (D-clear Study)

Recruiting·HHuahui Health·Phase 3·NCT07499544·160 enrolled

Prospective, Open-label, Multicenter Long-term Follow-up Study to Evaluate the Durability of Virologic Response in Participants With Chronic Hepatitis B Previously Treated With AHB-137 Injection

Recruiting·AAusper Biopharma Co., Ltd.·N/A·NCT07146100·200 enrolled

An Open-Label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Low-HBsAg Chronic Hepatitis B

Recruiting·AAusper Biopharma Co., Ltd.·Phase 2·NCT07137910·200 enrolled

Page 1 of 72

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)